Pharmafile Logo

News and Press Releases

Avallano Strengthens Leadership with New Chief Strategy Officer to Drive AI-Powered Clinical Research Innovation

26 June 2024 -- South Carolina, US -- Avallano, an AI-enabled clinical research company, today announced the appointment of Michael A Ibara PharmD, as chief strategy officer (CSO). Dr Ibara...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 26, 2024

Avallano
sales@avallano.com
Greenville, South Carolina, 29609

Thermo Fisher Scientific Expands Clinical Research Laboratory in Wisconsin

The PPD clinical research business' new laboratory will enhance services in new and emerging therapeutic areas, add 350 new jobs to region 18 June 2024 -- North Carolina, US --...

Category: BioManufacturing, Manufacturing and Packing, Pharmaceutical
Posted: June 19, 2024

Thermo Fisher Scientific
168 Third Avenue Waltham, MA 02451

Thermo Fisher Scientific Showcases Clinical Research Innovation at DIA Annual Meeting

PPD clinical research business leads real-world data and technology panel, receives CRO Leadership Award 17 June 2024 -- California, US -- The PPD clinical research business of Thermo Fisher Scientific,...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 17, 2024

Thermo Fisher Scientific
168 Third Avenue Waltham, MA 02451

Exonate appoints Dr Rafiq Hasan as Non-Executive Director

Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board 28 May 2024 -- Cambridgeshire, UK -- Exonate, a biotechnology company developing...

Category: Biotechnology, Pharmaceutical
Posted: May 28, 2024

Exonate
info@exonate.com
WTL Moorfield Rd Duxford Cambridgeshire CB22 4PS United Kingdom

Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease

Builds on preclinical proof-of-concept that MTX325 protects dopamine-producing brain cells by enhancing mitophagy – the process cells use to remove dysfunctional mitochondria 21 March 2024 -- Cambridge, UK -- Mission...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 21, 2024

Mission Therapeutics
info@missiontherapeutics.com
Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom

Bio-Rad Launches First Ultrasensitive Multiplexed Digital PCR Assay for Breast Cancer Mutation Detection in Clinical Research

Highly Sensitive and Multiplexed Assay for the Detection, Discrimination and Quantification of Key Mutations in ESR1 Gene for Breast Cancer, Developed for Bio-Rad’s QX600 Droplet Digital PCR System 2 April...

Category: Clinical Trials
Posted: April 2, 2024

Bio-Rad
UK_contact@bio-rad.com
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET

One2Treat launches ground-breaking treatment-decision approach to clinical research and market access analysis

One2Treat reflects patient priorities in a single comprehensive treatment evaluation, reducing trial sample size and accelerating patient access to new treatments 26 March 2024 -- Brussels, Belgium -- One2Treat, a...

Category: Clinical Trials, Pharmaceutical
Posted: March 26, 2024

One2Treat
info@one2treat.com
Rue Emile Francqui, 1-1435 Mont-Saint-Guibert, Belgium

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, Germany, researchers from the Mayo Clinic in Rochester, USA and HepaRegeniX HRX-215 proved to be safe and well...

Category: Biotechnology
Posted: March 15, 2024

WCG Expands New Statistical Consulting Solutions to Address Industry Resource Challenges

4 March 2024 -- New Jersey, US -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the expansion of its capabilities with the...

Category: Clinical Trials
Posted: March 4, 2024

WCG Clinical
info@wcgclinical.com
212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial

Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...

Category: Drug Discovery
Posted: February 7, 2024

Peptomyc
lsoucek@peptomyc.com
C/ Natzaret, 115-117 Barcelona, Spain, 08035

Thermo Fisher Scientific Announces Launch of Innovative CorEvitas Pharmacovigilance Platform for Clinical Research Registries

20 December 2023 -- Massachusetts, US -- Thermo Fisher Scientific, the world leader in serving science, today announced the launch of CorEvidence, a proprietary cloud-based data lake platform optimising pharmacovigilance...

Category: Clinical Trials
Posted: December 20, 2023

Thermo Fisher Scientific
168 Third Avenue Waltham, MA 02451